TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Verrica Pharmaceuticals ( (VRCA) ) has provided an announcement.
On July 24, 2025, Nasdaq notified Verrica Pharmaceuticals that its securities were subject to delisting due to non-compliance with the Minimum Bid Price Requirement. The company implemented a 1-for-10 reverse stock split to increase its stock price, which began trading on a split-adjusted basis on July 25, 2025. As of July 29, 2025, the stock price was $6.24, and the company plans to request a compliance determination after ten days of maintaining the required bid price.
The most recent analyst rating on (VRCA) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on Verrica Pharmaceuticals stock, see the VRCA Stock Forecast page.
Spark’s Take on VRCA Stock
According to Spark, TipRanks’ AI Analyst, VRCA is a Neutral.
Verrica Pharmaceuticals faces substantial financial challenges with persistent losses and negative equity, severely impacting its overall score. Technical analysis suggests potential bearish momentum, and valuation remains poor due to negative earnings. However, recent corporate events provide some optimism with strategic partnerships and financial stability efforts, slightly enhancing the outlook.
To see Spark’s full report on VRCA stock, click here.
More about Verrica Pharmaceuticals
Verrica Pharmaceuticals is a company operating in the pharmaceutical industry, primarily focused on developing and commercializing dermatological treatments.
Average Trading Volume: 47,552
Technical Sentiment Signal: Sell
Current Market Cap: $62.81M
See more insights into VRCA stock on TipRanks’ Stock Analysis page.